Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Breitenbuecher, Frank ^a   Hoffarth, Sandra ^a   Worm, Karl ^a   Cortes Incio, Diana ^a   Gauler, Thomas C ^a,b   Köhler, Jens ^a   Herold, Thomas ^a,c   Schmid, Kurt Werner ^a   Freitag, Lutz ^b   Kasper, Stefan ^a   Schuler, Martin ^a,b,c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER RECURRENCE; CELL COUNT; CELL FRACTIONATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; FEMALE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; PROCESS DEVELOPMENT; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SEQUENTIAL ANALYSIS; SOMATIC MUTATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; NUCLEIC ACID DENATURATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE-CELL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904605266     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085350     Document Type: Article

References (32)

1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. NEnglJMed 361: 947-957.
2. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. ClinCancer Res 14: 6302-6309.
3. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. NEnglJMed 351: 781-791. (Pubitemid 39095313)
4. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, et al. (2009) Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. AnnOncol 20: 1223-1229.
5. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, et al. (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-smallcell lung cancer. JClinOncol 29: 1556-1563.
6. Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, et al. (2012) Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. ClinCancer Res 18: 2391-2401.
7. Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, et al. (2012) Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. J Thorac Oncol 7: 306-315.
8. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, et al. (2012) Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer. Journal of Clinical Oncology 30: 525-532. doi:10.1200/JCO.2010.33.3716.
9. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, et al. (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. ClinCancer Res 13: 7053-7058. (Pubitemid 350276887)
10. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. NatRevCancer 2: 442-454.
11. Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277: 301-308. doi:10.1111/j.1742-4658.2009.07448.x.
12. Sequist LV, Yang JCH, Yamamoto N, O'Byrne K, Hirsh V, et al. (2013) Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung AdenocarcinomaWith EGFR Mutations. Journal of Clinical Oncology 31: 3327-3334. doi:10.1200/JCO.2012.44.2806.
13. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. NEnglJMed 362: 2380-2388.
14. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246.
15. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. NEnglJMed 366: 883-892.
16. Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, et al. (2007) Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). BrJCancer 97: 778-784. (Pubitemid 47396294)
17. Bai H, Mao L, Wang HS, Zhao J, Yang L, et al. (2009) Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. JClinOncol 27: 2653-2659.
18. Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, et al. (2009) Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant nonsmall cell lung cancer. ClinCancer Res 15: 2630-2636.
19. Buttitta F, Felicioni L, Del GM, Filice G, Di LA, et al. (2013) Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing. ClinCancer Res 19: 691-698.
20. Hsieh HB, Marrinucci D, Bethel K, Curry DN, Humphrey M, et al. (2006) High speed detection of circulating tumor cells. BiosensBioelectron 21: 1893-1899.
21. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, et al. (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. JClinOncol 23: 1420-1430.
22. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, et al. (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. JClinOncol 26: 3213-3221.
23. Sanger N, Effenberger KE, Riethdorf S, Van H V, Gauwerky J, et al. (2011) Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer 129: 2522-2526.
24. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, et al. (2011) Detection of circulating tumour cells with a hybrid (epithelial/ mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. British Journal of Cancer 105: 1338-1341. doi:10.1038/bjc.2011.405.
25. Hosokawa M, Kenmotsu H, Koh Y, Yoshino T, Yoshikawa T, et al. (2013) Size- Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System. PLoS ONE 8: e67466. doi:10.1371/journal.- pone.0067466.s003.
26. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. NEnglJMed 359: 366-377.
27. Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. DevCell 14: 818-829. (Pubitemid 351757205)
28. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, et al. (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339: 580-584.
29. Pailler E, Adam J, Barthélémy A, Oulhen M, Auger N, et al. (2013) Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. Journal of Clinical Oncology 31: 2273-2281. doi:10.1200/JCO.2012.44.5932.
30. Gundry M, Vijg J (2012) Mutation Research/Fundamental and MolecularMechanisms of Mutagenesis. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis 729: 1-15. doi:10.1016/j.mrfmmm.2011.10.001.
31. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B (2011) Detection and quantification of rare mutations with massively parallel sequencing. ProcNatlAcadSciUSA 108: 9530-9535. doi:10.1073/pnas.1105422108.
32. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, et al. (2012) Detection of ultra-rare mutations by next-generation sequencing. ProcNatlAcadSciUSA 109: 14508-14513. doi:10.1073/pnas.1208715109.